

SIERRA LEONE

Support for Human Papillomavirus Vaccine (HPV)

This Decision Letter sets out the Programme Terms of a Programme

1. Country:	Sierra Leone						
2. Vaccine grant number:	19-SLE-08f-Y, 1921-SLE-19b-X						
3. Date of Decision Letter:	9/30/2019						
4. Date of the Partnership Framework Agreement:	3/10/2013						
5. Programme title:	New Vaccine Support (NVS), HPV, Routine						
6. Vaccine type:	Human Papillomavirus Vaccine						
7. Requested product presentation and formulation of vaccine:	HPV Quadrivalent, 1 dose(s) per vial, LIQUID						
8. Programme Duration:¹	2019-2021						
9. Programme Budget (indicative):²	(subject to the terms of the Partnership Framework Agreement, if applicable)						
	2019	2020	2021	2022	2023	2024	Total ²
Programme Budget (US\$)	1,155,000	1,046,000	852,000	-	-	-	3,053,000
10. Vaccine introduction grant							
	Approval						
	Year	Grant Number					Amount (US\$)
	2019	19-SLE-08f-Y					255,322
11. Product switch grant	Not applicable						
12. Indicative Annual Amounts:³	(subject to the terms of the Partnership Framework Agreement, if applicable)						
Type of supplies to be purchased with Gavi funds	2019	2020					2021
Number of vaccine doses		229,700					-
Annual Amounts (US\$)	1,155,000	1,046,000					-
13. Procurement agency:	UNICEF. The Country shall release its co-financing payments each year to UNICEF.						

14. Self-procurement: Not applicable

15. Co-financing obligations:

According to the co-financing policy, the Country falls within the group: Initial self-financing

The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.

Type of supplies to be purchased with Country funds in each year	2020	2021	2022	2023	2024
Number of vaccine doses	35,800	8,600	-	-	-
Number of AD syringes	-	-	-	-	-
Number of re-constitution syringes	-	-	-	-	-
Number of safety boxes	-	-	-	-	-
Value of vaccine doses (US\$)	160,810	38,682	-	-	-
Total co-financing payments (US\$) (including freight)	163,000	39,500	-	-	-

16. Operational support for campaigns:
Not applicable

17. Additional Reporting Requirements:

	Due dates
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> Vaccine stock levels including buffer stock Number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received 	31 March 2020 15 May 2020
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Gavi Secretariat

18. Financial clarifications: Not applicable

19. Other conditions:

Not applicable

Signed by

On behalf of Gavi



Thabani Maphosa

Managing Director, Country Programmes

30 September 2019